Topic: neurodegenerative diseases
Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.
Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.
The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.
Mitochondria in diseased upper motor neurons of the brain go through a self-destructive process at an early stage of neurodegeneration in ALS.
Armed with $44 million, Arkuda Therapeutics is going after a protein that plays a role in neuronal health and lysosomal function to treat dementia.
Newly identified gene variants that play a role in MS-related vision loss could help guide precision medicine and drug development, researchers say.
The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.
Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.
By examining the role played by star-shaped brain cells called astrocytes, UCLA scientists identified a potential strategy to fight Huntington's.
The positive result tees Reata up to file for FDA approval of the activator of Nrf2 and expand development to other neurodegenerative diseases.